Correction to: Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma.

MLA

Kawamura, Yusuke, et al. “Correction to: Well-Preserved Liver Function Enhances the Clinical Impact of Curative-Intent Subsequent Treatment during Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.” Clinical Journal of Gastroenterology, vol. 16, no. 5, Oct. 2023, p. 791. EBSCOhost, https://doi.org/10.1007/s12328-023-01825-7.

APA

Kawamura, Y., Akuta, N., Shindoh, J., Matsumura, M., Okubo, S., Tominaga, L., Fujiyama, S., Hosaka, T., Saitoh, S., Sezaki, H., Suzuki, F., Suzuki, Y., Ikeda, K., Arase, Y., Hashimoto, M., Kozuka, T., & Kumada, H. (2023). Correction to: Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology, 16(5), 791. https://doi.org/10.1007/s12328-023-01825-7

Chicago

Kawamura, Yusuke, Norio Akuta, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Licht Tominaga, Shunichiro Fujiyama, et al. 2023. “Correction to: Well-Preserved Liver Function Enhances the Clinical Impact of Curative-Intent Subsequent Treatment during Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.” Clinical Journal of Gastroenterology 16 (5): 791. doi:10.1007/s12328-023-01825-7.